Title: Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.
Journal: Molecular oncology 20140501
Title: mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.
Journal: Virology 20140301
Title: PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20130801
Title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Journal: Bioorganic & medicinal chemistry letters 20130301
Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
Journal: British journal of cancer 20120925
Title: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Journal: Leukemia 20120601
Title: Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis.
Journal: The Biochemical journal 20120515
Title: TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.
Journal: Cell metabolism 20120502
Title: Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
Journal: Cancer research 20120401
Title: Mammalian target of rapamycin (mTOR) inhibition reduces cerebral vasospasm following a subarachnoid hemorrhage injury in canines.
Journal: Experimental neurology 20120201
Title: Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Journal: PloS one 20120101
Title: Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
Journal: The Journal of biological chemistry 20111118
Title: Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Journal: Cancer research 20110801
Title: mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Journal: Cancer discovery 20110617
Title: mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Journal: Cancer research 20110615
Title: Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Journal: Biochemical Society transactions 20110401
Title: Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice.
Journal: British journal of cancer 20110329
Title: Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Journal: Journal of medicinal chemistry 20110310
Title: Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
Journal: Bioorganic & medicinal chemistry letters 20100801
Title: Mammalian autophagy: core molecular machinery and signaling regulation.
Journal: Current opinion in cell biology 20100401
Title: AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Journal: Cancer research 20100101
Title: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Journal: Nature 20090716
Title: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
Journal: Current biology : CB 20040727
Title: Regulation of longevity and stress resistance by Sch9 in yeast.
Journal: Science (New York, N.Y.) 20010413
Title: Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298.
Title: You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31.
Title: Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.